Lixte Biotechnology appoints Dr. René Bernards as independent director

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Dr. René Bernards appointed to board; he is a leader in molecular carcinogenesis at Netherlands Cancer Institute.
Co-founded four biotech companies; member of Royal Netherlands Academy of Sciences, AACR Fellow.
Presented new data at AACR on effectiveness of lead compound LB-100 with various anti-cancer agents.
Compensation: one-time $100k cash fee and annual $40k payable quarterly in lieu of stock options.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. René Bernards

director

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2022-06-15
Filed: June 17, 2022, 7:59 PM ET

Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. René Bernards was appointed as director at LIXTE BIOTECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: director

Exact text from the filing

Effective as of June 15, 2022, the Company’s Board of Directors (the “Board”) appointed Dr. René Bernards to the Board as an independent director.

View on SEC.gov

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-017017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.